NGM Live signals | Maximize Profits with Getagraph.com

BUY 102205 min ago

@ $1.435

Issued: 14 Feb 2024 @ 15:31

Return: 7.32%

Previous signal: Feb 14 - 09:52

Previous signal: Sell

Return: -3.68 %

Live Chart Being Loaded With Signals

Commentary (4 Apr 2024 @ 16:00):

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer...

Stats
Today's Volume	0.00
Average Volume	969 866
Market Cap	128.53M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.300 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.890
ATR14	$0.00400 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Tcg Opportunity Iii Gp, Llc	Buy	1 000	Common Stock
2024-04-05	Tcg Opportunity Iii Gp, Llc	Sell	44 000	Common Stock
2024-04-05	Column Group Gp, Lp	Buy	1 000	Common Stock
2024-04-05	Column Group Gp, Lp	Sell	44 000	Common Stock
2024-04-05	Column Group L P	Buy	1 000	Common Stock

INSIDER POWER
-56.32
Last 100 transactions
Buy: 3 241 050 \| Sell: 9 885 031

Volume Correlation

Long: -0.36 (neutral)

Short: 0.00 (neutral)

Signal:(48.109) Neutral

NGM Biopharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NGM Biopharmaceuticals Correlation - Currency/Commodity

-0.83
( strong negative )

-0.76
( moderate negative )

0.00
( neutral )

0.09
( neutral )

NGM Biopharmaceuticals Financials

Annual	2023
Revenue:	$4.42M
Gross Profit:	$2.20M (49.72 %)
EPS:	$-1.730

Q4	2023
Revenue:	$165 000
Gross Profit:	$-353 000 (-213.94 %)
EPS:	$-0.330

Q3	2023
Revenue:	$582 000
Gross Profit:	$82 000.00 (14.09 %)
EPS:	$-0.350

Q2	2023
Revenue:	$1.42M
Gross Profit:	$304 000 (21.36 %)
EPS:	$-0.460

Financial Reports:

No articles found.

NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.